Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life SciencesNSE:ALIVUS -1.39%80 EV-to-EBITDA is 18.12 as of Aug. 24, 2026, which is 35% above its 10-year median of 13.39. GuruFocus rates NSE:ALIVUS with a GF Score™ of 80/100 and a GF Value™ of ₹1,035.68 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 739 Drug Manufacturers companies, Alivus Life Sciences ranks worse than 63.19% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alivus Life Sciences's enterprise value is ₹160,364 Mil.
Alivus Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹8,849 Mil. Therefore, Alivus Life Sciences's EV-to-EBITDA for today is 18.12.
The historical rank and industry rank for Alivus Life Sciences's EV-to-EBITDA or its related term are showing as below:
NSE:ALIVUS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.75 Med: 13.39 Max: 24.17
Current: 18.12
During the past 8 years, the highest EV-to-EBITDA of Alivus Life Sciences was 24.17. The lowest was 6.75. And the median was 13.39.
NSE:ALIVUS's EV-to-EBITDA is ranked worse than 63.19% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.2
vs NSE:ALIVUS: 18.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alivus Life Sciences (NSE:ALIVUS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alivus Life Sciences's PE Ratio (TTM) for today is calculated as:
Alivus Life Sciences's share price for today is ₹1366.10.
Alivus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹49.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alivus Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's EV-to-EBITDA falls into.
Alivus Life Sciences's current Enterprise Value is ₹160,364 Mil.
Alivus Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,849 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a EV-to-EBITDA of 18.12 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alivus Life Sciences. This is 35% above median its historical median of 13.39. Over the past decade, Alivus Life Sciences' EV-to-EBITDA has ranged from 6.75 to 24.17. According to the industry distribution chart, Alivus Life Sciences ranks #467 out of 739 companies in the Drug Manufacturers industry, placing it in the top 63.2%.
Is Alivus Life Sciences' EV-to-EBITDA too high?
Alivus Life Sciences' current EV-to-EBITDA of 18.12 is 35% above median its 10-year median of 13.39. Over the past 10 years, this metric has ranged from a low of 6.75 to a high of 24.17. The Drug Manufacturers industry median EV-to-EBITDA is 13.20. Alivus Life Sciences' value of 18.12 is 37.3% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #467 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alivus Life Sciences has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #467 out of 739 companies for EV-to-EBITDA. This places Alivus Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.20. Alivus Life Sciences' value of 18.12 is 37.3% above this benchmark. Historically, Alivus Life Sciences' own EV-to-EBITDA has ranged from 6.75 to 24.17 over the past decade. While the company's 10-year median is 13.39 vs. the industry median of 13.20, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.20, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current EV-to-EBITDA of 18.12 is 37.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alivus Life Sciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current EV-to-EBITDA is 18.12, which is 35% above median its own 10-year median of 13.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,035.68, compared to a current price of ₹1,366.10 — trading 31.9% above its estimated fair value. The current EV-to-EBITDA is 18.12, which is 35% above median its 10-year median of 13.39 and 37.3% above the Drug Manufacturers industry median of 13.20. Alivus Life Sciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current EV-to-EBITDA is 18.12 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,366.10 is trading 31.9% above its estimated GF Value™ of ₹1,035.68.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
EV-to-EBITDA: 18.12 (35% above median its 10-year median of 13.39)
GF Value™: ₹1,035.68 vs. price of ₹1,366.10 (31.9% above fair value)
Industry Position: 37.3% above the Drug Manufacturers median (#467 of 739)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
80GF Score
Get the complete analysis for NSE:ALIVUS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
